Theravance Biopharma (NASDAQ:TBPH) Hits New 12-Month High – Should You Buy?

Theravance Biopharma, Inc. (NASDAQ:TBPH) hit a new 52-week high on Saturday . The company traded as high as $10.90 and last traded at $10.47, with a volume of 508066 shares trading hands. The stock had previously closed at $9.67.

Theravance Biopharma Stock Performance

The firm has a fifty day simple moving average of $9.47 and a 200-day simple moving average of $8.92. The company has a market capitalization of $514.81 million, a PE ratio of -10.37 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. During the same quarter last year, the firm posted ($0.17) EPS. As a group, research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. This represents a 1.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors have recently added to or reduced their stakes in TBPH. BNP Paribas Financial Markets boosted its holdings in shares of Theravance Biopharma by 88.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after buying an additional 143,781 shares during the period. Marshall Wace LLP lifted its holdings in Theravance Biopharma by 83.6% in the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after acquiring an additional 135,426 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Theravance Biopharma in the second quarter valued at approximately $986,000. Algert Global LLC bought a new position in shares of Theravance Biopharma during the third quarter valued at approximately $851,000. Finally, Bank of Montreal Can raised its position in shares of Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after purchasing an additional 93,702 shares during the period. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.